Clinical Insight In clinical trials, weekly injectable Tirzepatide produced A1C reductions up to 2.0% and 1420% weight loss over 72 weeks
In addition to the well-documented nausea, vomiting, heartburn, bloating, constipation, diarrhea and muscle loss, more serious side effects think pancreatitis, gastrointestinal obstruction, thyroid tumors and vision issues have also been reported.
Overeating while on GLP-1 RAs can lead to significant discomfort
Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
A Personalized Approach Weight loss is not one-size-fits-all
Recently, modification of the gut flora by supplementation with prebiotics has been considered to be a potential therapeutic strategy to reduce uremic toxins of intestinal origin and inflammation